Abiopharma

🔍 Xu Jiandong (Executive)

Company: Estrella Immunopharma, Inc. (ESLA)

Report Date: 2026-08-18

Detailed Transactions and Holdings:

• Acquired 100,000 shares of Common Stock, par value $0.0001 per share at $0.815 per share (Direct)
  Date: 2026-08-18 | Code: M | equity_swap_involved: 0 | shares_owned_after: 365,488.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 100,000 shares of Incentive Share Option at $0.815 per share (Derivative)
  Date: 2026-08-18 | Code: M | Expires: 2034-10-29 | Exercise: 2024-10-31 | equity_swap_involved: 0 | shares_owned_after: 390,796.00 | transaction_form_type: 4 | Footnotes: F3, F4, F3

Footnotes:

• F1: Represents the exercise price per share paid by the Reporting Person upon the exercise of the stock options reported in Table II.
• F2: Reflects the 265,488 shares of Common Stock directly beneficially owned as reported on the Reporting Person's most recent Form 4, plus the 100,000 shares acquired upon the reported exercise.
• F3: Represents incentive share options granted to the Reporting Person on October 30, 2024 under the Issuer's 2023 Omnibus Incentive Plan, of which twenty-five percent (25%) was immediately exercisable on the date of grant, with the remainder vesting in equal monthly installments of 1/48th of the total award on each monthly anniversary of October 30, 2024. The options were vested as to the shares exercised.
• F4: Not applicable - the reported transaction is the exercise of the stock option for the exercise price set forth in Column 2; no separate consideration was paid or received for the derivative security.